The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations

Wednesday, October 19, 2011

Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations11:17 EDT Wednesday, October 19, 2011THOUSAND OAKS, Calif., Oct. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Anthony (Tony) Hooper, executive vice president, Global Commercial Operations, effective October 26th. In this role, Hooper will report to Robert A. Bradway, president and chief operating officer, and will be responsible for the Company's Global Commercial Operations. Hooper, 56, joins Amgen after sixteen years at Bristol-Myers Squibb Company (BMS) where he was most recently senior vice president, Commercial Operations and president, United States, Japan and Intercontinental.  Hooper's broad commercial operations experience includes running the BMS commercial business in North America, Asia, Middle East, Africa, South America and Europe.  "As we continue to grow, Tony's track record of delivering results and his passion for serving patients across the globe make him an outstanding addition to Amgen's leadership team," Bradway said."It's a privilege to join Amgen, a Company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses," said Hooper. "I am looking forward to bringing my global commercial experience to Amgen as it moves to implement its strategic vision for growth and international expansion."About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen. CONTACT: Amgen, Thousand OaksChristine Regan, 805-447-5476 (media)Arvind Sood, 805-447-1060 (investors)(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)SOURCE Amgen